Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 7, 2012, Pages

  Serrano, Antonia ^a,b   Pavón, Francisco J ^a,b   Suarez, Juan ^a,b   Rivera, Patricia ^a   Vida, Margarita ^a   Bermúdez Silva, Francisco J ^a,b   Alonso, Mónica ^a   Martínez, Ana ^c   López Ogalla, Javier ^d   Alonso Gascón, Mercedes ^d   Santamaría, Gema ^d   Romero Cuevas, Miguel ^a,b   Pérez Valero, Vidal ^a   Baixeras, Elena ^a   de Fonseca, Fernando Rodríguez ^a,b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c CSIC   (Spain)

^d Noscira   (Spain)

Author keywords

Diet induced obesity; Fatty liver; Feeding behavior; Glucose; Insulin

Indexed keywords

ADIPONECTIN; ANTIOBESITY AGENT; GLUCOSE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NP 1; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CONTROLLED STUDY; DIETARY INTAKE; FATTY LIVER; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MALAISE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; TASTE AVERSION; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPONECTIN; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BLOTTING, WESTERN; BODY WEIGHT; CELL LINE; DIET, HIGH-FAT; DIETARY FATS; EATING; FATTY LIVER; GLUCOSE TOLERANCE TEST; LIPID METABOLISM; LIVER; MALE; MYOBLASTS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TASTE; THIAZOLES; WEIGHT GAIN;

EID: 84859476049     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00468.2011     Document Type: Article

References (36)

1. Alonso M, Serrano A, Vida M, Crespillo A, Hernandez-Folgado L, Jagerovic N, Goya P, Reyes-Cabello C, Perez-Valero V, Decara J, Macías-González M, Bermúdez-Silva FJ, Suárez J, de Fonseca FR, Pavón FJ. Antiobesity Efficacy of Lh-21, a Cannabinoid Cb(1) Receptor Antagonist with Poor Brain Penetration, in Diet-Induced Obese Rats. Br J Pharmacol. In press.
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
3. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 9: RA55-RA61, 2003.
4. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953, 2001.
5. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84-89, 2002.
6. Beylot M, Pinteur C, Peroni O. Expression of the adiponectin receptors AdipoR1 and AdipoR2 in lean rats and in obese Zucker rats. Metabolism 55: 396-401, 2006.
7. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
8. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21: 3-16, 2001.
9. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adi-pocyte-specific secretory protein adiponectin. Diabetes 52: 268-276, 2003.
10. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145: 367-383, 2004.
11. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007, 2002.
12. Crespillo A, Alonso M, Vida M, Pavón FJ, Serrano A, Rivera P, Romero-Zerbo Y, Fernández-Llebrez P, Martínez A, Pérez-Valero V, Bermúdez-Silva FJ, Suárez J, de Fonseca FR. Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. Br J Pharmacol 164: 1899-1915, 2011.
13. Crespillo A, Suárez J, Bermúdez-Silva FJ, Rivera P, Vida M, Alonso M, Palomino A, Lucena MA, Serrano A, Pérez-Martín M, Macias M, Fernández-Llébrez P, Rodríguez de Fonseca F. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J 433: 175-185, 2010.
14. de Oliveira C, de Mattos AB, Biz C, Oyama LM, Ribeiro EB, do Nascimento CM. High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations. Lipids Health Dis 10: 11, 2011.
15. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010, 2001.
16. González-Yanes C, Serrano A, Bermúdez-Silva FJ, Hernández-Dominguez M, Páez-Ochoa MA, Rodríguez de Fonseca F, Sánchez-Margalet V. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 289: E923-E929, 2005.
17. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785, 2007.
18. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
19. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703, 1996.
20. Martinez Gil A, Alonso Caston M, Santamaria Nunez G, Martinez Diez M, Lopez Ogalla J. N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases. World International Patent No. WO2009019202, 2009.
21. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152: 113-118, 2005.
22. Pavon FJ, Bilbao A, Hernández-Folgado L, Cippitelli A, Jagerovic N, Abellán G, Rodríguez-Franco MA, Serrano A, Macias M, Gómez R, Navarro M, Goya P, Rodríguez de Fonseca F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharma-cology 51: 358-366, 2006.
23. Peng Y, Rideout D, Rakita S, Sajan M, Farese R, You M, Murr MM. Downregulation of adiponectin/AdipoR2 is associated with steatohepatitis in obese mice. J Gastrointest Surg 13: 2043-2049, 2009.
24. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52: 667-674, 2003.
25. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737, 2004.
26. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 12: 365-383, 2010.
27. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749, 1995.
28. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Maki-mattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53: 2169-2176, 2004.
29. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935, 2001.
30. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112: 91-100, 2003.
31. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidia-betic metabolic effects. Nature 423: 762-769, 2003.
32. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.
33. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461-2468, 2003.
34. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.
35. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: 2968-2974, 2002.
36. Zhou M, Xu A, Lam KS, Tam PK, Che CM, Chan L, Lee IK, Wu D, Wang Y. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. J Hepatol 53: 1108-1116, 2010.